Skip to content

Study · Randomized controlled trial · n = 30 · 2026

2 results

Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial.

Mercer DF, Mubekapi-Musadaidzwa C, Kloster B, Berner-Hansen M, Rydén A, Jeppesen PB

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition12 Mar 2026

PMID41816796 (opens in a new tab)PMCIDPMC13419254 (opens in a new tab)DOI10.1002/ncp.70109 (opens in a new tab)PepBankPUB-41816796
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

BackgroundA randomized, double-blind, placebo-controlled trial was conducted to evaluate efficacy and safety of glepaglutide in patients who have short bowel syndrome with intestinal failure (SBS-IF). At the end of the trial, exit interviews were conducted to explore participants' experiences and to assess the impact of the disease and treatment during the trial.MethodsThirty patients from four countries were interviewed over the phone. Data were collected using a semistructured interview manual, and interviews were recorded and transcribed for analysis.ResultsPatients reported that SBS-IF negatively impacted their lives before the trial, causing loss of freedom, disrupted sleep, limited physical activity, and pain. During the interviews, patients reported that the treatment improved their well-being across multiple domains. Seventy-three percent of the patients receiving glepaglutide (n = 16/22) reported positive changes in health-related quality of life compared with 25% receiving placebo (n = 2/8). Twenty-six patients reported experiencing a reduction in parenteral support (PS) volume. Of these, 21 patients (18 glepaglutide, three placebo) reported a change in overall status, with 94% receiving glepaglutide (n = 17/18) and 67% (n = 2/3) receiving the placebo finding this change meaningful. Although descriptive, these findings should be interpreted cautiously given the small number of patients.ConclusionDuring exit interviews, patients receiving glepaglutide reported improvements in well-being across multiple domains, noting meaningful reductions in PS volume and a reduced impact of SBS-IF on daily life, which was proportionally greater than in those receiving placebo. These findings underscore the patient-reported positive experiences of glepaglutide and its beneficial effects.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In interviewed patients with SBS-IF, 73% receiving glepaglutide reported positive quality-of-life changes versus 25% receiving placebo.

    In plain wordsIn patients with SBS-IF, 73% receiving glepaglutide reported better quality of life versus 25% receiving placebo.

    Peptide
    Glepaglutide
    Outcome
    IncreasePositive health-related quality of life changes
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Quality of life · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Patients reporting positive health-related quality-of-life change
    73%
    Glepaglutide, 16/22
    Patients reporting positive health-related quality-of-life change
    25%
    Placebo, 2/8

    Source sentences

    Summary
    Seventy-three percent of the patients receiving glepaglutide (n = 16/22) reported positive changes in health-related quality of life compared with 25% receiving placebo (n = 2/8).
    3 context sentences
    Summary · context
    A randomized, double-blind, placebo-controlled trial was conducted to evaluate efficacy and safety of glepaglutide in patients who have short bowel syndrome with intestinal failure (SBS-IF).
    Summary · context
    At the end of the trial, exit interviews were conducted to explore participants' experiences and to assess the impact of the disease and treatment during the trial.
    Summary · context
    Thirty patients from four countries were interviewed over the phone.
  2. 02HumanRandomized controlled trialEfficacy outcome

    Among patients reporting an overall status change, 94% receiving glepaglutide found it meaningful versus 67% receiving placebo.

    In plain wordsAmong patients reporting a status change, 94% receiving glepaglutide found it meaningful versus 67% receiving placebo.

    Peptide
    Glepaglutide
    Outcome
    IncreaseMeaningful change in overall status
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Quality of life · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Patients finding the status change meaningful
    94%
    Glepaglutide, 17/18
    Patients finding the status change meaningful
    67%
    Placebo, 2/3

    Source sentences

    Summary
    Of these, 21 patients (18 glepaglutide, three placebo) reported a change in overall status, with 94% receiving glepaglutide (n = 17/18) and 67% (n = 2/3) receiving the placebo finding this change meaningful.
    3 context sentences
    Summary · context
    A randomized, double-blind, placebo-controlled trial was conducted to evaluate efficacy and safety of glepaglutide in patients who have short bowel syndrome with intestinal failure (SBS-IF).
    Summary · context
    At the end of the trial, exit interviews were conducted to explore participants' experiences and to assess the impact of the disease and treatment during the trial.
    Summary · context
    Thirty patients from four countries were interviewed over the phone.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.